Scientists make anti-cancer compounds
Washington, Feb 13 (IANS) Yale University scientists have streamlined the process for synthesising a family of compounds that can potentially kill cancer and other diseased cells, representing a unique category of anti-cancer agents.
Read more on MalaysiaNews.net
Skin Cancer of the eyelids poses several diagnostic and management challenge. As a referral specialist, I see these patients well after a significant progression has occurred and the diagnosis is fairly obvious. The excision and reconstruction if these tumors requires a great degree of creativity and flexibility to achieve the optimal result.
The ultraviolet radiation that is primarily responsible for malignant transformation of skin cancer are 290 to 320 nm(UV-B). The most common malignancies affecting the periocular region are basal cell carcinoma, squamous cell carcinoma, sebaceous cell carcinoma, and malignant melanoma. Basal cell carcinoma accounts for 90% of all eyelid malignancies. The tumor primarily involves the lower eyelid (50% to 66%) and the medial canthus (25% to 30%). The upper eyelid is affected in 15% of cases and the lateral canthus in 5%. Although these statistics are helpful, many skin cancers involve adjacent anatomic areas such as the forehead and cheek, and pose even greater challenges in reconstruction.
» Read more: Eyelid Skin Cancer
FDA Approves Novel Prostate Cancer “Vaccine”
The treatment, which works by turning the body’s immune system against invading cancer cells, is called Provenge and is manufactured by Seattle biotech firm Dendreon
Read more on Time Magazine